Healthcare -
Biotechnology - NASDAQ - CA
$ 1.17
-3.31 %
$ 5.13 M
Market Cap
-0.69
P/E
1. INTRINSIC VALUE
Balance Sheet
Clearmind Medicine Inc.
| Current Assets | 7.09 M |
| Cash & Short-Term Investments | 6.86 M |
| Receivables | 181 K |
| Other Current Assets | 44.2 K |
| Non-Current Assets | 167 K |
| Long-Term Investments | 0 |
| PP&E | 51.7 K |
| Other Non-Current Assets | 116 K |
| Current Liabilities | 4.13 M |
| Accounts Payable | 526 K |
| Short-Term Debt | 36.7 K |
| Other Current Liabilities | 3.57 M |
| Non-Current Liabilities | 16.4 K |
| Long-Term Debt | 16.4 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Clearmind Medicine Inc.
| Revenue | 0 |
| Cost Of Revenue | 26.7 K |
| Gross Profit | -26.7 K |
| Operating Expenses | 5.72 M |
| Operating Income | -6.3 M |
| Other Expenses | -1.05 M |
| Net Income | -5.25 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clearmind Medicine Inc.
| Net Income | -5.25 M |
| Depreciation & Amortization | 51.1 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 884 K |
| Change in Working Capital | -130 K |
| Others | -708 K |
| Free Cash Flow | -4.86 M |
Wall Street Analysts Price Targets
Clearmind Medicine Inc.
CMND has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CMND does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Clearmind Medicine Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Impact Acquisition Enters Into Definitive Agreement to Complete Qualifying Transaction with Jeffs Brands and Fort Products
February 6, 2025 – TheNewswire - Vancouver, British Columbia – Impact Acquisition Corp. (TSXV: IMPC.P) (“ Impact ”, the “ Company ” or the “ Resulting Issuer ”) is pleased to announce that further to its press release on January 3, 2025, the Company, Jeffs' Brands Ltd, a corporation incorporated under the laws of the State of Israel and listed on the NASDAQ under the trading symbol “JFBR” (“ Jeffs Brands ” or “ JFBR ”), and Jeffs Brands' wholly owned subsidiary, Fort Products Limited (the “ Target ” or “ Fort Products ”) has entered into a definitive agreement dated February 6, 2025 (the “ Definitive Agreement ”), in respect of an arm's length share sale transaction involving the Target Shares (as defined below) (the “ Proposed Transaction ”), which will result in the reverse takeover of the Company by Jeffs Brands. The Proposed Transaction is expected to constitute the Company's “Qualifying Transaction” as such term is defined in policies of the TSX Venture Exchange (the “ Exchange ”). The Proposed Transaction
thenewswire.com
- 3 weeks ago
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial (IMPI), the National Mexico Patent Office. The patent refers to the Company's innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
globenewswire.com
- 3 weeks ago
Clearmind Medicine Announces Shareholders Meeting Results
Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the “Meeting”), as set out in the Company's Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as auditor of the Company, a resolution to establish and approve an omnibus equity incentive plan and a resolution allowing the directors, if they deem such an action to be in the best interest of shareholders, effect a consolidation (the “Consolidation”) of the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company's board of directors.
globenewswire.com
- 1 month ago
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
globenewswire.com
- 1 month ago
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office.
globenewswire.com
- 1 month ago
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format
globenewswire.com
- 2 months ago
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).
globenewswire.com
- 2 months ago
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company that has developed ActivCrystal™ technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odorless, made from natural ingredients, and designed to be sprinkled on meals. The two companies plan to collaborate on the development and commercialization of Clearmind's proprietary MEAI-based alcohol substitute and Dr Glitter Pty Ltd's proprietary ActivCrystal™ technology.
globenewswire.com
- 2 months ago
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval from one of its clinical sites in the U.S. for part A of its Phase I/IIa clinical trial in the United States for treating patients suffering from alcohol use disorder (AUD). The multinational, multi-center trial will assess the safety, tolerability, and pharmacokinetics of Clearmind's innovative MEAI-based (5-methoxy-2-aminoindane) treatment, CMND-100.
globenewswire.com
- 4 months ago
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care
globenewswire.com
- 5 months ago
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the International Patent Cooperation Treaty (“PCT”).
globenewswire.com
- 5 months ago
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments
globenewswire.com
- 5 months ago
8. Profile
Summary
Clearmind Medicine Inc. CMND
COUNTRY
CA
INDUSTRY
Biotechnology
MARKET CAP
$ 5.13 M
Dividend Yield
0.00%
Description
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Contact
1220 West 6th Avenue, Vancouver, BC, V6H 1A5
https://www.clearmindmedicine.com
IPO
Date
Nov. 15, 2022
Employees
4
Officers
Dr. Adi Zuloff-Shani Ph.D.
Chief Executive Officer
Ms. Adi Varon
Controller
Prof. Mark Haden M.S.W.
Vice President of Business Development
Ms. Mylene Touboul
Accounting Manager